Drawing for ITM PASSION FOR PRECISION

USPTO serial 90447337

ITM PASSION FOR PRECISION

Reviewed by CopyMark Law Group

Reg. 6546779Status 700Renewal
Filing date
Status date
Registration date
Nov 2, 2021
Examiner
WILKE, JOHN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ITM PASSION FOR PRECISION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kari Moyer-Henry

KARI MOYER-HENRY LEWIS KOHN & WALKER LLP17085 VIA DEL CAMPOSAN DIEGO, CA 92127UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseasesACTIVE—
010Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; control, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposesACTIVE—
042Conducting clinical trials in all stages and with various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)ACTIVE—
044Medical services, in particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 3, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 10, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
May 19, 2022ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Nov 2, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 17, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 17, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 28, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 13, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 12, 2021DOCKASSIGNED TO EXAMINER—
Apr 3, 2021MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 2, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 28, 2021TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jan 28, 2021PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jan 7, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance